Alteration of Intestinal Dysbiosis by Fecal Microbiota Transplantation Does not Induce Remission in Patients with Chronic Active Ulcerative Colitis
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In patients with ulcerative colitis (UC), alterations of the intestinal microbiota, termed dysbiosis, have been postulated to contribute to intestinal inflammation. Fecal microbiota transplantation (FMT) has been used as effective therapy for recurrent Clostridium difficile colitis also caused by dysbiosis. The aims of the present study were to investigate if patients with UC benefit from FMT and if dysbiosis can be reversed. METHODS: Six patients with chronic active UC nonresponsive to standard medical therapy were treated with FMT by colonoscopic administration. Changes in the colonic microbiota were assessed by 16S rDNA-based microbial community profiling using high-throughput pyrosequencing from mucosal and stool samples. RESULTS: All patients experienced short-term clinical improvement within the first 2 weeks after FMT. However, none of the patients achieved clinical remission. Microbiota profiling showed differences in the modification of the intestinal microbiota between individual patients after FMT. In 3 patients, the colonic microbiota changed toward the donor microbiota; however, this did not correlate with clinical response. On phylum level, there was a significant reduction of Proteobacteria and an increase in Bacteroidetes after FMT. CONCLUSIONS: FMT by a single colonoscopic donor stool application is not effective in inducing remission in chronic active therapy-refractory UC. Changes in the composition of the intestinal microbiota were significant and resulted in a partial improvement of UC-associated dysbiosis. The results suggest that dysbiosis in UC is at least in part a secondary phenomenon induced by inflammation and diarrhea rather than being causative for inflammation in this disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These reports were followed by a number of small studies of FMT in children and adults with UC, CD, and pouchitis with mixed results.64–72”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [69]
Citations
Cites
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887
Search and clustering orders of magnitude faster than BLAST
Edgar, R. C. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq461 · Cited by 20,826
UniFrac: a New Phylogenetic Method for Comparing Microbial Communities
Lozupone, C., & Knight, R. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.12.8228-8235.2005 · Cited by 8,227
Diversity of the Human Intestinal Microbial Flora
Eckburg, P. B., Bik, E. M., Bernstein, C. N., Purdom, E., Dethlefsen, L., Sargent, M., Gill, S. R., Nelson, K. E., & Relman, D. A. (2005) · Science · doi:10.1126/science.1110591 · Cited by 7,913 · cited 1×
“, 16S rDNA) in combination with highthroughput sequencing techniques that enabled culture-independent surveys of human gut microbes.(32) Using these techniques, remarkable changes in the human gut microbiota in patients with IBD have been observed.”
The Ribosomal Database Project: improved alignments and new tools for rRNA analysis
Cole, J. R., Wang, Q., Cardenas, E., Fish, J., Chai, B., Farris, R. J., Kulam-Syed-Mohideen, A. S., McGarrell, D. M., Marsh, T., Garrity, G. M., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn879 · Cited by 4,762 · cited 1×
“5.(25) Contaminant (human) sequences and singletons were manually removed.”
BackgroundFrank, D. N., St. Amand, A. L., Feldman, R. A., Boedeker, E. C., Harpaz, N., & Pace, N. R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706625104 · Cited by 4,611 · cited 2×
“Using these techniques, remarkable changes in the human gut microbiota in patients with IBD have been observed.(6,30,33,34) These changes, also termed dysbiosis, are thought to be involved in the pathogenesis of IBD.”
BackgroundMethodDuodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708 · cited 3×
“Changes of the intestinal microbiota after FMT have so far been studied only in recurrent CDI.(13,43) Successful FMT in CDI was associated with an increase in bacterial diversity and richness,(13,43) an increase of Bacteroidetes, Firmicutes, and butyrate-producing bacteria such as Lachnospiraceae, and a decrease in Pr…”
BackgroundCoated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis
Schroeder, K. W., Tremaine, W. J., & Ilstrup, D. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198712243172603 · Cited by 3,026 · cited 1×
“During control visits, the clinical condition and endoscopic activity of UC were judged using the Mayo score.(20) A reduction of the total Mayo score by $3 points was considered as a clinical response, whereas a drop of the Mayo score to #2 points was considered as remission.”
MethodFord Alexander, C., Paul, M., Hanauer Steven, B., 谭蓓, & Dong, W. Z. (2001) · Cited by 3,020
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
Morgan, X. C., Tickle, T. L., Sokol, H., Gevers, D., Devaney, K. L., Ward, D. V., Reyes, J. A., Shah, S. A., LeLeiko, N., Snapper, S. B., et al. (2012) · Genome Biology · doi:10.1186/gb-2012-13-9-r79 · Cited by 2,713
Research works printed but not linked: 1
- Lee, 2010, 330, 1768
Cited by
Items 101–200 of 234
Ishikawa, D., Sasaki, T., Takahashi, M., Kuwahara‐Arai, K., Haga, K., Ito, S., Okahara, K., Nakajima, A., Shibuya, T., Osada, T., et al. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy266 · Cited by 59
Enteric microbiota leads to new therapeutic strategies for ulcerative colitis
Chen, W.-X., Ren, L., & Shi, R. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i42.15657 · Cited by 64
The potential therapeutic role of Lactobacillus reuteri for treatment of inflammatory bowel disease.
Wang, H., Zhou, C., Huang, J., Kuai, X., & Shao, X. (2020) · PubMed Central · Cited by 68
Kedia, S., Rampal, R., Paul, J., & Ahuja, V. (2016) · Journal of Gastroenterology · doi:10.1007/s00535-016-1193-1 · Cited by 56
Li, M., Wang, B., Sun, X., Tang, Y., Wei, X., Ge, B.-Y., Tang, Y., Deng, Y., He, C., Yuan, J., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00824 · Cited by 58
“However, some unfavorable outcomes of FMT were also reported (9).”
BackgroundLi, W., Sun, Y., Dai, L., Chen, H., Yi, B., Niu, J., Wang, L., Zhang, F., Luo, J., Wang, K., et al. (2021) · BMC Microbiology · doi:10.1186/s12866-021-02201-6 · Cited by 58
“For example, Ishikawa et al. [25, 26] found that FMT following antibiotic pretreatment can effectively improve gut dysbiosis caused by loss of Bacteroidetes in UC patients.”
BackgroundZhao, H. L., Chen, S. Z., Xu, H. M., Zhou, Y. L., He, J., Huang, H. L., Xu, J., & Nie, Y. Q. (2020) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12933 · Cited by 48
Fecal microbiota transplantation: current clinical efficacy and future prospects
Surawicz, C. M., Bowman, K. A., & Broussard, E. K. (2015) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s61305 · Cited by 53
“treated with single colonoscopic FMT demonstrated transient clinical improvement in all patients, yet none of the patients achieved clinical remission.(48) Two RCTs of FMT for UC have just been published; both were stopped early due to futility.”
Verbeke, K., Boesmans, L., & Boets, E. (2014) · Proceedings of The Nutrition Society · doi:10.1017/s0029665114000639 · Cited by 51
Microbe-metabolite-host axis, two-way action in the pathogenesis and treatment of human autoimmunity
Meng, X. L., Zhou, H., Shen, H., Lufumpa, E., Li, X., Guo, B., & Li, B. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.03.006 · Cited by 47
Fecal Microbiota Transplantation: From Clostridium difficile to Inflammatory Bowel Disease.
Gianotti, R. J., & Moss, A. C. (2017) · Europe PMC (PubMed Central) · Cited by 53
Allegretti, J. R., Eysenbach, L. M., El‐Nachef, N., Fischer, M., Kelly, C. R., & Kassam, Z. (2017) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000001247 · Cited by 48
Canadian Association of Gastroenterology Position Statement: Fecal Microbiota Transplant Therapy
Moayyedi, P., Marshall, J. K., Yuan, Y., & Hunt, R. H. (2014) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2014/346590 · Cited by 44
Caenepeel, C., Deleu, S., Vázquez-Castellanos, J. F., Arnauts, K., Braekeleire, S., Machiels, K., Baert, F., Mana, F., Pouillon, L., Hindryckx, P., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.05.017 · Cited by 51
Current stage in inflammatory bowel disease: What is next?
Gómez, G. J., Masedo, Á., Yela, C., Martínez-Montiel, M. D. P., & Casís, B. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i40.11282 · Cited by 47
Microbiome modulates intestinal homeostasis against inflammatory diseases
Sun, X., & Jia, Z. (2018) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2018.10.014 · Cited by 48
Fecal transplantation for ulcerative colitis: current evidence and future applications
Lopetuso, L. R., Ianiro, G., Allegretti, J. R., Bibbò, S., Gasbarrini, A., Scaldaferri, F., & Cammarota, G. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1733964 · Cited by 43
Pathway-based approaches to the treatment of inflammatory bowel disease
Bamias, G., Pizarro, T. T., & Cominelli, F. (2015) · Translational research · doi:10.1016/j.trsl.2015.09.002 · Cited by 44
“of studies, the effect of FMT on flora composition of recipients was also examined (45, 46).”
BackgroundZhang, T., Cui, B., Li, P., He, Z., Long, C., Wei, L., Peng, Z., Ji, G., & Zhang, F. (2016) · PLOS ONE · doi:10.1371/journal.pone.0158227 · Cited by 39
“Rossen et al[13] and Kump et al[31] reported no benefit was achieved from FMT in patients with UC.”
BackgroundRecipe for IBD: can we use food to control inflammatory bowel disease?
Witkowski, M., Witkowski, M., Gagliani, N., & Huber, S. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0658-5 · Cited by 44
“The intense application of 40 FMT during 8 weeks and pooling stool of up to seven donors was the factor which distinguished this trial from recent studies that failed to induce remission, although fecal microbiota changes could be observed [143, 144].”
ResultBasson, A. R., Lam, M. C., & Cominelli, F. (2017) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2017.08.002 · Cited by 42
Mizuno, S., Nanki, K., Matsuoka, K., Saigusa, K., Ono, K., Arai, M., Sugimoto, S., Kiyohara, H., Nakashima, M., Takeshita, K., et al. (2017) · Intestinal Research · doi:10.5217/ir.2017.15.1.68 · Cited by 40
“Much effort has been involved in determining whether FMT is effective against patients with active UC.(2,12,16) In Canada and the Netherlands, Moayyedi et al.”
InfluentialCammarota, G., Ianiro, G., Bibbò, S., & Gasbarrini, A. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000244 · Cited by 36
Sun, D., Li, W., Li, S., Cen, Y., Xu, Q., Li, Y., Sun, Y., Qi, Y., Lin, Y., Yang, T., et al. (2016) · Medicine · doi:10.1097/md.0000000000003765 · Cited by 44
Perturbation of the Human Microbiome as a Contributor to Inflammatory Bowel Disease
Missaghi, B., Barkema, H. W., Madsen, K., & Ghosh, S. (2014) · Pathogens · doi:10.3390/pathogens3030510 · Cited by 40
“, have reported no clinical improvement in small series of patients with UC [102].”
BackgroundFecal microbial transplant for the treatment of pediatric inflammatory bowel disease
Wang, A. Y., Popov, J., & Pai, N. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i47.10304 · Cited by 38
Qiao, Y., Cai, C., & Ran, Z. H. (2016) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12422 · Cited by 42
Fecal Transplant in Inflammatory Bowel Disease
Browne, A. S., & Kelly, C. R. (2017) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2017.08.005 · Cited by 44
Glycans as critical regulators of gut immunity in homeostasis and disease
Dias, A. M., Pereira, M. S., Padrão, N., Alves, I., Marcos‐Pinto, R., Lago, P., & Pinho, S. S. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.07.007 · Cited by 38
Recurrent Clostridium difficile infection and the microbiome
Almeida, R., Gerbaba, T. K., & Petrof, E. O. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-015-1099-3 · Cited by 38
“Although FMT has demonstrated overall safety among the immunocompromised population, a subset of patients with inflammatory bowel disease (IBD) have been found to experience exacerbation of IBD, fever, or elevated C-reactive protein levels post-FMT treatment [83– 86].”
Levast, B., Fontaine, M., Nancey, S., Déchelotte, P., Dore, J. M., & Lehert, P. (2023) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000568 · Cited by 35
Reciprocal interaction of diet and microbiome in inflammatory bowel diseases
Schaubeck, M., & Haller, D. (2015) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000216 · Cited by 35
Fecal Microbiota Transplantation and Its Potential Therapeutic Uses in Gastrointestinal Disorders
Heath, R. D., Cockerell, C., Mankoo, R., Ibdah, J. A., & Tahan, V. (2017) · Northern Clinics of Istanbul · doi:10.14744/nci.2017.10692 · Cited by 36
“, 2013 [51] Cohort study Colonoscopy 6 Positive”
BackgroundChronic Inflammatory Diseases: Are We Ready for Microbiota-based Dietary Intervention?
Viennois, É., Gewirtz, A. T., & Chassaing, B. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.02.008 · Cited by 31
Houari, A. E., Écale, F., Mercier, A., Crapart, S., Laparre, J., Soulard, B., Ramnath, M., Berjeaud, J., Rodier, M., & Crépin, A. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.828359 · Cited by 29
Fecal Microbiota Transplantation for Gastrointestinal Diseases
Matsuoka, K., Mizuno, S., Hayashi, A., Hisamatsu, T., Naganuma, M., & Kanai∥, T. (2014) · The Keio Journal of Medicine · doi:10.2302/kjm.2014-0006-re · Cited by 36
How to Manipulate the Microbiota: Fecal Microbiota Transplantation
Fuentes, S., & de Vos, W. M. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-31248-4_10 · Cited by 31
Clinical Review on the Utility of Fecal Microbiota Transplantation in Immunocompromised Patients
Abu‐Sbeih, H., Ali, F. S., & Wang, Y. (2019) · Current Gastroenterology Reports · doi:10.1007/s11894-019-0677-6 · Cited by 29
Ren, R., Gao, X., Shi, Y., Li, J., Peng, L., Sun, G., Wang, Z., Yan, B., Zhi, J., & Yang, Y. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.742255 · Cited by 28
“The long-term outcomes and health consequences of FMT remain to be established, with most studies reporting mixed results and without showing a sustained benefit of FMT (Brandt et al., 2012; Kump et al., 2013; Vermeire et al., 2016).”
BackgroundResultConover, K. R., Absah, I., Ballal, S. A., Brumbaugh, D. E., Cho, S., Cardenas, M. C., Knackstedt, E. D., Goyal, A., Jensen, M. K., Kaplan, J. L., et al. (2023) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000003714 · Cited by 32
“However, it is important to consider that patients with rCDI have expansion of invasive bacterial species including members of the genus Enterobacteriaceae (28,29).”
BackgroundAsk, Don't Tell — Mobile Phones to Improve HIV Care
Högenauer, C., & Bhatt, A. S. (2013) · Cited by 25
Self-citationInflammatory bowel disease and the gut microbiota
Wu, N., Mah, C., Koentgen, S., Zhang, L., Grimm, M., El-Omar, E. M., & Hold, G. L. (2021) · Proceedings of The Nutrition Society · doi:10.1017/s002966512100197x · Cited by 30
“In contrast, no clinical improvement was observed in two smaller studies((87,88)).”
Mahmoudi, H., & Hossainpour, H. (2022) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_131_22 · Cited by 27
“Some of the short‐term side effects of transplantation include: flatulence, diarrhea, constipation, borborygmus, vomiting, and transient serious events.[10,15,54,55] More serious adverse events related to the method of administration of FMT can occur, though they are rare.”
BackgroundCao, Y., Zhang, B., Wu, Y., Wang, Q., Wang, J., & Shen, F. (2018) · Gastroenterology Research and Practice · doi:10.1155/2018/5480961 · Cited by 33
“There were three articles reported on the Shannon diversity index (SDI) with a measure of the colonic bacterial diversity on pre-FMT and post-FMT in UC patients [21, 43, 57].”
BackgroundMethodBrace, C., Gloor, G. B., Ropeleski, M. J., Allen‐Vercoe, E., & Petrof, E. O. (2014) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2014.01.020 · Cited by 23
Role of fecal microbiota transplantation in inflammatory bowel disease
D'Odorico, I., Bella, S. D., Monticelli, J., Giacobbe, D. R., Boldock, E., & Luzzati, R. (2018) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12603 · Cited by 26
“(2016) Not related to recipient (4) Frozen Vermeire et al.(35) (2016) Relative (4), friend (10) Frozen Wei et al.”
BackgroundFaecal microbiota transplantation—the Austrian approach
Kump, P. K., Krause, R., Allerberger, F. J., & Högenauer, C. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12801 · Cited by 23
“Whereas a single application of FMT, as is recommended for patients with CDI, seems to be without major benefit for UC patients [28,29], a protocol using repeated FMT has shown a clinical response in approximately 50% of patients [30].”
BackgroundMethodSelf-citationFecal Microbiota Transplantation in Inflammatory Bowel Disease: A Primer for Internists
Syal, G., Kashani, A., & Shih, D. Q. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.03.010 · Cited by 26
Weese, J. S., Nichols, J., Jalali, M., & Litster, A. (2015) · Veterinary Microbiology · doi:10.1016/j.vetmic.2015.08.012 · Cited by 20
Bradyrhizobium enterica in Cord Colitis Syndrome
Bhatt, A. S., Marty, F. M., & Meyerson, M. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1311318 · Cited by 19
Al‐Ali, D., Ahmed, A., Shafiq, A., McVeigh, C., Châari, A., Zakaria, D., & Bendriss, G. (2021) · Qatar medical journal · doi:10.5339/qmj.2021.5 · Cited by 22
Hot topics on fecal microbiota transplantation for the treatment of inflammatory bowel disease
Zhang, X., Ishikawa, D., Ohkusa, T., Fukuda, S., & Nagahara, A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1068567 · Cited by 19
Methodology, Not Concept of Fecal Microbiota Transplantation, Affects Clinical Findings
Cui, B., Xu, F., & Zhang, F. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.065 · Cited by 17
Trasplante de microbiota fecal
de Paredes, A. G. G., de Santiago, E. R., Aguilera, L., Ferre‐Aracil, C., & López–Sanromán, A. (2014) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2014.07.010 · Cited by 29
Changes of intestinal microbiota and microbiota-based treatments in IBD
Li, Q., Zhou, S., Wang, Y., & Cong, J. (2022) · Archives of Microbiology · doi:10.1007/s00203-022-03069-4 · Cited by 16
Kong, L., Chen, S., Huang, S., Zheng, A., Gao, S., Ye, J., & Hua, C. (2024) · Inflammation Research · doi:10.1007/s00011-024-01854-z · Cited by 18
“However, some research has also shown that FMT has limited efficacy in treating IBD [92, 93].”
Faecal microbiota transplantation in children : A systematic review
Lauwers, E., Sabino, J., Hoffman, I. E. A., & van Hoeve, K. (2024) · Acta Paediatrica · doi:10.1111/apa.17167 · Cited by 18
Kump, P. K., & Högenauer, C. (2016) · Digestive Diseases · doi:10.1159/000447379 · Cited by 14
Self-citationHuman microbiome: From the bathroom to the bedside
Malnick, S. D. H., & Melzer, E. (2015) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v6.i3.79 · Cited by 17
Zatorski, H., & Nakov, R. (2020) · Current Drug Targets · doi:10.2174/1389450121666200602125507 · Cited by 13
Microbial Modulation in Inflammatory Bowel Diseases
Yu, J., & Cheon, J. H. (2022) · Immune Network · doi:10.4110/in.2022.22.e44 · Cited by 15
Faecal microbiota transplantation—A clinical view
Mattner, J., Schmidt, F., & Siegmund, B. (2016) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2016.02.003 · Cited by 12
INTESTINAL MICROBIOTA MUTUALISM AND GASTROINTESTINAL DISEASES
Tomasello, G., Sinagra, E., Zeenny, M., Jurjus, A. R., Giammanco, M., Majo, D. D., Traina, G., Damiani, P., Zein, R. J., & Leone, A. (2026) · EuroMediterranean Biomedical Journal · doi:10.3269/1970-5492.2015.10.1 · Cited by 15
Faecal Microbiota Transplantation as Emerging Treatment in European Countries
Maida, M. F., Mcilroy, J. R., Ianiro, G., & Cammarota, G. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-72799-8_11 · Cited by 14
Sorrentino, D. R., Nguyen, V. Q. C., & Chitnavis, M. V. (2019) · Cells · doi:10.3390/cells8060548 · Cited by 13
“Finally, one single treatment of FMT does not appear enough to achieve remission in IBD [106] as it is often the case for the treatment of Clostridioides difficile infection.”
Lübbert, C., Salzberger, B., & Mössner, J. (2017) · Der Internist · doi:10.1007/s00108-017-0203-6 · Cited by 24
“negativ aus [26, 27]; in einer Studie wurden in der FMT-Gruppe mehr Remissionen gefunden [28].”
Huang, T., Xu, J., Wang, M., Pu, K., Li, L., Zhang, H., Liang, Y., Sun, W., & Wang, Y. (2022) · Medicine · doi:10.1097/md.0000000000029790 · Cited by 15
“Uygun et al (2017)([34]) — — * * * * * * 6 Nishida et al (2016)([35]) — — * * * * * * 6 Mizuno et al (2017)([36]) — — * * * * * * 6 Jacob et al (2017)([37]) — — * * * * * — 5 Vermeire et al (2015)([38]) — — * * * * * * 6 Wei et al (2015)([39]) — — * * * * * * 6 Damman et al (2015)([40]) — — * * * * * * 6 Cui et al (20…”
A Physicians' Wish List for the Clinical Application of Intestinal Metagenomics
Klymiuk, I., Högenauer, C., Halwachs, B., Thallinger, G., Fricke, W. F., & Steininger, C. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001627 · Cited by 11
Self-citationRamos, R. J., Zhu, C., Joseph, D. F., Thaker, S., LaComb, J. F., Markarian, K., Lee, H., Petrov, J. C., Monzur, F., Buscaglia, J. M., et al. (2022) · Medical Research Archives · doi:10.18103/mra.v10i10.3318 · Cited by 10
Li, M., Li, Z., Shu, W., Liu, Y., Wang, Y., & Tang, L. (2016) · Future Microbiology · doi:10.2217/fmb-2015-0002 · Cited by 13
Is Crohn’s Disease Ready for Fecal Microbiota Transplantation?
Borody, T. J., Finlayson, S., & Paramsothy, S. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000155 · Cited by 12
Cui, B., Li, P., Xu, L., Peng, Z., Zhao, Y., Wang, H., He, Z., Zhang, T., Ji, G., Wu, K., et al. (2015) · Inflammation and Cell Signaling · doi:10.14800/ics.757 · Cited by 9
“Conversely, Patrizia K [18] reported that no efficacy was shown in six patients with refractory UC by a single colonoscopic FMT.”
BackgroundBrittnacher, M., Heltshe, S. L., Hayden, H. S., Radey, M. C., Weiss, E. J., Damman, C. J., Zisman, T. L., Suskind, D. L., & Miller, S. I. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158897 · Cited by 9
“For example, successful treatment of recurrent Clostridium difficile[38–40, 42, 45, 46] induced colitis with fecal microbiota transplantation (FMT) has stimulated research in evaluating the effectiveness of FMT as therapy for ulcerative colitis (UC)[37, 44], Crohn's disease (CD)[47] and other inflammatory bowel diseas…”
BackgroundWang, H., Liu, S.-P., Ma, T., Yan, W., Zhou, J.-F., Shi, Y., Shen, P., Yang, X., & Wu, S.-N. (2018) · Medicine · doi:10.1097/md.0000000000010675 · Cited by 11
Tungland, B. C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814649-1.00009-0 · Cited by 10
Fecal Microbiota Transplantation for Ulcerative Colitis. Are We Ready for Primetime?
Cheng, Y., & Fischer, M. (2020) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2020.08.006 · Cited by 12
Lopetuso, L. R., Laterza, L., Petito, V., Pecere, S., Quaranta, G., CHIERICO, F. D., Puca, P., Schiavoni, E., Napolitano, D., Poscia, A., et al. (2023) · Microorganisms · doi:10.3390/microorganisms11102536 · Cited by 8
Trasplante de microbiota fecal: primer caso reportado en Chile y revisión de la literatura
Espinoza, R., Quera, R., Meyer, L., & Rivera, D. (2014) · Revista chilena de infectología · doi:10.4067/s0716-10182014000400016 · Cited by 15
Fecal Microbiota Transplantation: Expanding Horizons for Clostridium difficile Infections and Beyond
Borody, T. J., Peattie, D. A., & Mitchell, S. (2015) · Antibiotics · doi:10.3390/antibiotics4030254 · Cited by 9
“Later they used multiple FMT infusions, which achieved significant improvement from baseline [43], and noted that serially repeated FMT produced better efficacy than a single FMT [43].”
BackgroundIntestinales Mikrobiom und chronisch-entzündliche Darmerkrankungen: Feindschaft oder Freundschaft?
Bürger, M., Lange, K. S., & Stallmach, A. (2015) · Die Gastroenterologie · doi:10.1007/s11377-014-0963-7 · Cited by 7
Conservation Metagenomics: Understanding Microbiomes for Biodiversity Sustenance and Conservation
Akoijam, N., & Joshi, S. R. (2022) · Springer eBooks · doi:10.1007/978-981-16-6005-4_3 · Cited by 8
Jansen, D., Deleu, S., Caenepeel, C., Marcelis, T., Simsek, C., Falony, G., Machiels, K., Sabino, J., Raes, J., Vermeire, S., et al. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2499575 · Cited by 7
Newman, K. M., & Vaughn, B. P. (2020) · Minerva Gastroenterologica e Dietologica · doi:10.23736/s1121-421x.19.02610-2 · Cited by 6
Stallmach, A., Grunert, P., Pieper, D. H., & Steube, A. (2019) · Zeitschrift für Gastroenterologie · doi:10.1055/a-0874-6603 · Cited by 8
“…et al. 2013 [62] NJT Fieber und CRP-Erhöhung (5/5), Diarrhö (5/5), Flatulenz (1/5), Erythem (1/5), Übelkeit 1/5) Pankreatitis (1/5) Kump et al. 2013 [63] Koloskopie Diarrhö und Fieber (1/6) keine Kunde et al. 2013 [64] Einläufe Blähungen (9/9), abdominelle Krämpfe (6/9), Diarrhö…”
Faecal transplantation for IBD management—pitfalls and promises
Quraishi, M. N., Critchlow, T., Bhala, N. B., Sharma, N., & Iqbal, T. H. (2017) · British Medical Bulletin · doi:10.1093/bmb/ldx040 · Cited by 9
Ding, X. L., Yang, X., & Wang, H. (2020) · Medicine in Microecology · doi:10.1016/j.medmic.2020.100028 · Cited by 10
In Vivo and In Vitro Studies on Dietary Fiber and Gut Health
Campos-Vega, R., Oomah, B. D., & Vergara‐Castañeda, H. A. (2016) · Wiley eBooks · doi:10.1002/9781119138105.ch6 · Cited by 12
Remodelling the gut ecosystem: a dysbiosis model to elucidate gut-organ axis dynamics in mice
Krishnapriya, Kishanchand, D. K., Rishikesh, R., Venkatachalam, S., Alikunju, A. P., Deepti, A., Sivan, U., & Sasidharan, B. C. P. (2025) · Physiology & Behavior · doi:10.1016/j.physbeh.2025.115000 · Cited by 6
Saha, J., & Goswami, R. (2025) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-025-10807-9 · Cited by 9
“In spite of certain observations where disease remission was not satisfactorily achieved in patients of active UC [239, 240], FMT had been in current interest in potential mitigation of bowel-related diseases.”
Deterding, K., Spinner, C. D., Schott, E., Welzel, T. M., Gerken, G., Klinker, H., Spengler, U., Wiegand, J., Wiesch, J. S. Z., Pathil, A., et al. (2016) · United European Gastroenterology Journal · doi:10.1177/2050640616678364 · Cited by 6
Fecal Microbiota Transplantation
Borody, T. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-54843-4.00018-0 · Cited by 7
Innate immunity and inflammatory bowel disease: a review of clinical evidence and future application
Katakura, K., Watanabe, H., & Ohira, H. (2013) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-013-0436-4 · Cited by 6
“Although one of them has recently shown that FMT could not induce remission in UC patients [35], FMT should be considered as an alternative therapy for IBD and further accumulation of data will be expected.”
BackgroundSignal Versus Noise: How to Analyze the Microbiome and Make Progress on Antimicrobial Resistance
Golob, J. L., & Rao, K. K. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab184 · Cited by 4
The role of the fecal microbiota in inflammatory bowel disease
Khalaf, R., Sciberras, M., & Ellul, P. (2024) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002818 · Cited by 5
“However, some of the results were confounding as a decrease in Bacteroidetes and an increase in Firmicutes or vice versa was noted [29,50,75,82,89–95].”
Evaluation of microbial and vancomycin treatments in ulcerative colitis in murine models
Hasan, N., & Yang, H. (2023) · PLoS ONE · doi:10.1371/journal.pone.0285613 · Cited by 6
Hmar, E. B. L., Paul, S., Boruah, N., Sarkar, P., Borah, S., & Sharma, H. K. (2021) · Current Pathobiology Reports · doi:10.1007/s40139-020-00218-6 · Cited by 4
Fecal Microbiota Transplantation: An Interview with Alexander Khoruts
Lebeau, S., & Khoruts, A. (2014) · Global Advances in Health and Medicine · doi:10.7453/gahmj.2014.020 · Cited by 4
Chen, H., Yi, B., Liu, Q., Xu, X., Dai, L., & Ma, Z. S. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.724661 · Cited by 3
“For instance, understanding the inter-individual heterogeneity is essential for studying and implementing microbiome intervention treatments such as fecal transplantation for treating certain microbiome-associated diseases (Kump et al., 2013; Wei et al., 2015; Weingarden and Vaughn 2017; Ishikawa et al., 2017, 2018; C…”
BackgroundGut Homeostasis; Microbial Cross Talks in Health and Disease Management
Khatri, G. S., Kurian, C., Anand, A., & Paari, K. A. (2021) · Current Research in Nutrition and Food Science Journal · doi:10.12944/crnfsj.9.3.28 · Cited by 3
FMT in Clostridium difficile and Other Potential Uses
Fine, S., & Kelly, C. R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804024-9.00034-3 · Cited by 3
Metadata
- Authors
- Kump, P. K., Gröchenig, H.-P., Lackner, S., Trajanoski, S., Reicht, G., Hoffmann, K. M., Deutschmann, A., Wenzl, H. H., Petritsch, W., Krejs, G. J., Gorkiewicz, G., & Högenauer, C.
- Affiliations
- Medical University of Graz (AT)
- Hospital of the Brothers of St. John of God (AT)
- Venue
- Inflammatory Bowel Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-09
- Volume
- 19
- Issue
- 10
- Pages
- 2155-2165
- ISSN
- 1078-0998 (ISSN-L)
- OpenAlex
- W1983728610
- Cited by
- 235
- References
- 49
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 7 · 2023: 7 · 2022: 9 · 2021: 11 · 2020: 17 · 2019: 16 · 2018: 19 · 2017: 28 · 2016: 32 · 2015: 41 · 2014: 35 · 2013: 6
- FWCI
- 25.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Inflammatory Bowel Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
- Keywords
- fecal microbiota transplantation, ulcerative colitis
- MeSH terms
- Adolescent, Adult, Biological Therapy, Chronic Disease, Clostridium Infections, Colitis, Ulcerative, Feces, Female, Follow-Up Studies, Humans, Intestines, Male, Middle Aged, Phylogeny, Prognosis, Remission Induction, RNA, Ribosomal, 16S, Transplantation, Metagenome, Microbiota, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.